Program
ENV-294
A development code. Also written as “ENV-294 Capsule”.
Its studies are mostly in Dermatitis, Atopic · Asthma, led by Enveda Therapeutics.
Furthest: phase 2, since Dec 10, 20254 company-led studies, 3 open or runningNext primary completion: Dec 2026 (phase 2)
Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| Enveda Therapeutics | 43 open or running | phase 2since Dec 10, 2025 | Sep 20, 2025 | Dec 2026phase 2 · NCT07298395 |
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
- Sep 20, 2025First study: phase 1 study in Dermatitis, AtopicFirst studyNCT07336940 · 9 enrolled · United States
- Dec 10, 20252 phase 2 studiesPhase 2 reachedNCT07301255, NCT07298395
- Jun 7, 2026Phase 2 study in Dermatitis, AtopicNCT07643766 · 200 planned · United States
Ahead
- Dec 2026Primary completion: phase 2 study in AsthmaNCT07301255
- Dec 2026Primary completion: phase 2 study in Dermatitis, AtopicNCT07298395
- Dec 2027Primary completion: phase 2 study in Dermatitis, AtopicNCT07643766
TargetBeta
Not stated by its company or a source we have read. Most early programs say nothing of it.
Studies
All 4 led by companies developing it, newest first. Each opens its study page.
| Study | Phase | Status | Primary completion | Size |
|---|---|---|---|---|
| NCT07643766Dermatitis, Atopic · United States | 2 | Recruiting | Dec 2027 | 200 |
| NCT07301255Asthma · United States | 2 | Recruiting | Dec 2026 | 50 |
| NCT07298395Dermatitis, Atopic · United States | 2 | Recruiting | Dec 2026 | 105 |
| NCT07336940Dermatitis, Atopic · United States | 1 | Completed | Jan 13, 2026 | 9 |
How it is read
Names in the registry
- “ENV-294”, 3 entries
- “ENV-294 Capsule”, 1 entry
Codes read as this program: ENV294.
Conditions, from the studies’ own filings
- Dermatitis, Atopic, 3 studies
- Asthma, 1 study
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.